https://www.selleckchem.com/pr....oducts/cordycepin.ht
Anti-PD-1 antibody is the standard therapy for treatment-resistant gastric cancer, but only a limited number of patients respond. Additionally, cases of hyper-progressive disease (HPD) in which tumor growth accelerates after anti-PD-1 antibody administration have been reported; however, the biological mechanism has not been elucidated. In the present case, metastatic gastric cancer was treated with the anti-PD-1 antibody, nivolumab, as third-line treatment. After the initiation of nivolumab therapy, a rapidly enlarging para-aortic ly
Like
Comment
Share
